Pfizer Inc. (NYSE:PFE) Shares Sold by Schnieders Capital Management LLC

Schnieders Capital Management LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 26.1% during the 4th quarter, Holdings Channel reports. The firm owned 49,993 shares of the biopharmaceutical company’s stock after selling 17,672 shares during the quarter. Schnieders Capital Management LLC’s holdings in Pfizer were worth $1,439,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of PFE. Briaud Financial Planning Inc acquired a new position in Pfizer in the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the third quarter worth $34,000. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the fourth quarter valued at $36,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE:PFE traded up $0.06 during trading hours on Tuesday, reaching $26.32. 24,286,365 shares of the company were exchanged, compared to its average volume of 42,105,117. The stock’s 50-day moving average is $27.07 and its 200-day moving average is $28.52. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The firm has a market cap of $149.04 billion, a PE ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.